3 completed, 1 terminated. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
Follow Aimmune Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy AR201 powder, Placebo powder - Hen Egg Allergy | Phase 2 | Terminated | Aimmune Therapeutics, Inc. | 15 | 2019-08-20 | 2022-03-10 |
| Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy) Dupilumab, Placebo matching dupilumab, AR101 - Peanut Allergy | Phase 2 | Completed | Regeneron Pharmaceuticals | 148 | 2018-10-03 | 2024-02-07 |
| Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study AR101 - Peanut protein capsule - Peanut Allergy | Phase 2 | Completed | Aimmune Therapeutics, Inc. | 47 | 2014-08-27 | 2021-11-09 |
| Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT AR101 powder provided in capsules, Placebo powder provided in capsules - Peanut Allergy | Phase 2 | Completed | Aimmune Therapeutics, Inc. | 56 | 2014-02-06 | 2021-11-30 |
Peanut Hypersensitivity (3) · Hypersensitivity (2) · Food Hypersensitivity (1)
United States (4)